Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CYTX Cytori Therapeutics (CYTX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrends About Cytori Therapeutics Stock (NASDAQ:CYTX) 30 days 90 days 365 days Advanced Chart Ad Crypto 101 MediaBlackrock’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Cytori Therapeutics alerts:Sign Up Key Stats Today's Range$1.33▼$1.3850-Day Range$0.20▼$0.2152-Week Range$0.20▼$0.75Volume31,414 shsAverage Volume915,302 shsMarket Capitalization$30.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCytori Therapeutics, Inc. is a late stage cell therapy company, which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in San Diego, CA.Read More… Blackrock’s Sending THIS Crypto Higher on Purpose (Ad)Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Receive CYTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytori Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CYTX Stock News HeadlinesCytori Cell Research Institute Inc.August 10, 2024 | wsj.comCheckpoint Therapeutics Inc (CKPT)February 9, 2024 | investing.comBlackrock’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… November 5, 2024 | Crypto 101 Media (Ad)Sage Therapeutics Inc SAGENovember 4, 2023 | morningstar.com5 Biotech Stocks Under $10 Blasting HigherSeptember 27, 2023 | thestreet.comWomen’s Health Therapeutics Market Research Report by Type, Distribution Channel, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19October 16, 2022 | finance.yahoo.com8 Stocks Under $10 Ripping HigherAugust 29, 2022 | thestreet.comSee More Headlines CYTX Stock Analysis - Frequently Asked Questions How were Cytori Therapeutics' earnings last quarter? Cytori Therapeutics Inc (NASDAQ:CYTX) issued its earnings results on Tuesday, May, 14th. The biotechnology company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.02. The biotechnology company had revenue of $0.70 million for the quarter. Cytori Therapeutics had a negative trailing twelve-month return on equity of 272.70% and a negative net margin of 242.60%. When did Cytori Therapeutics' stock split? Shares of Cytori Therapeutics reverse split before market open on Thursday, May 24th 2018. The 1-10 reverse split was announced on Wednesday, May 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Cytori Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cytori Therapeutics investors own include Regulus Therapeutics (RGLS), Inovio Pharmaceuticals (INO), Shire (SHPG), Bank of America (BAC), BCE (BCE), Celldex Therapeutics (CLDX) and Micron Technology (MU). Company Calendar Last Earnings5/14/2019Today11/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & Medical Instruments Sub-IndustryBiotechnology Current SymbolNASDAQ:CYTX CUSIP23283K10 CIK1095981 Webwww.cytori.com Phone858-458-0900FaxN/AEmployees37Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,630,000.00 Net Margins-242.60% Pretax MarginN/A Return on Equity-272.70% Return on Assets-56.23% Debt Debt-to-Equity Ratio0.39 Current Ratio0.46 Quick Ratio0.30 Sales & Book Value Annual Sales$3.67 million Price / Sales8.21 Cash FlowN/A Price / Cash FlowN/A Book Value$0.35 per share Price / Book3.89Miscellaneous Outstanding Shares22,160,000Free FloatN/AMarket Cap$30.14 million OptionableNot Optionable Beta1.96 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:CYTX) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredMissed Out On Nvidia?Artificial Intelligence is a tool with the potential to create massive distributions of wealth… In fact, it...Unstoppable Prosperity | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Crypto 101 Media | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytori Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytori Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.